Novo Nordisk (NVO) CEO Lars Fruergaard Jorgensen discusses the drugmaker's difficulties in meeting demand for its flagship obesity drug, Wegovy, and when it could be launched in other markets. The group has just raised its earnings outlook due to strong demand, and is refraining from releasing a series of highly interesting cardiovascular data, as they would further increase demand. 
 
(MT Newswires)

Bloomberg videos